Document is current
Any future updates will be listed below
-
Authors
Arango, Celso
Baeza, Inmaculada
Bernardo, Miquel
Cañas, Fernando
de Dios, Consuelo
Díaz-Marsá, Marina
García-Portilla, María Paz
Gutiérrez-Rojas, Luis
Olivares, José Manuel
Rico-Villademoros, Fernando
Rodríguez-Jiménez, Roberto
Sánchez-Morla, Eva María
Segarra, Rafael
Crespo-Facorro, Benedicto
-
Funding
Funding for this research was provided by:
Sanofi
Merck
Instituto de Salud Carlos III
Fundación Alicia Koplowitz
Instituto de Investigación Sanitaria Fundación Jiménez Díaz (S2010/BMD-2422 AGES, FIS)
Ministerio de Economía y Competitividad
Eli Lilly and Company
Centro de Investigación Biomédica en Red de Salud Mental
Lundbeckfonden
Roche
Otsuka Pharmaceutical
Eusko Jaurlaritza
Eli Lilly and Company
Gedeon Richter
Ministry of Education, Culture, Sports, Science and Technology
Shire
Servier
H. Lundbeck A/S
Ministerio de Ciencia e Innovación
European Commission
Pfizer
- License Information
-
More Information
This article is maintained by: Elsevier
Article Title: Long-acting injectable antipsychotics for the treatment of schizophrenia in Spain
Journal Title: Revista de Psiquiatría y Salud Mental (English Edition)
CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rpsmen.2018.03.004
CrossRef DOI link to the associated document: https://doi.org/10.1016/j.rpsm.2018.03.006
Content Type: article
Copyright: © 2018 SEP y SEPB. Published by Elsevier España, S.L.U. All rights reserved.
